Gout Therapeutics

A Global Strategic Business Report

MCP21896

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

716

EXECUTIVE POOL

5850

PRICE

143

EXPERT INPUTS

42

COMPANIES

207

DATA TABLES

279

PAGES

8

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (16305)

734

CXO

653

VICE PRESIDENT

4772

DIRECTOR

8521

MANAGER

1625

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Gout Therapeutics Market to Reach US$10.8 Billion by 2030

The global market for Gout Therapeutics estimated at US$5.1 Billion in the year 2024, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2024-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Urate-Lowering Agents segment is estimated at 15.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 17.5% CAGR

The Gout Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 17.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 11.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.

Global Gout Therapeutics Market - Key Trends and Drivers Summarized

How Is the Gout Therapeutics Market Evolving with the Rise in Chronic Diseases?

Gout is a chronic form of arthritis caused by elevated levels of uric acid in the blood, leading to the formation of painful crystals in joints. Gout therapeutics are essential in managing this condition, which is becoming increasingly common due to lifestyle factors such as poor diet, obesity, and the aging population. The rising prevalence of gout is prompting a growing demand for effective therapies that can manage both acute flare-ups and long-term uric acid levels. Traditional treatments like nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine are still widely used, but there is a significant shift towards novel urate-lowering therapies, such as xanthine oxidase inhibitors and biologics, aimed at providing better control of the condition and minimizing side effects.

What Are the Key Segments and Types of Gout Therapeutics?

Drug classes include NSAIDs, corticosteroids, colchicine, and urate-lowering therapies such as allopurinol, febuxostat, and pegloticase. Urate-lowering drugs are gaining more attention due to their efficacy in preventing recurrences and managing chronic gout. The market can also be divided into acute and chronic treatment types, where acute treatments are aimed at relieving pain and inflammation during a flare-up, while chronic treatments focus on lowering uric acid levels to prevent future attacks. Oral medications dominate the market, but injectable biologics are increasingly being used in severe cases of refractory gout. Geographically, North America and Europe lead the market due to high disease prevalence and advanced healthcare infrastructure, while the Asia-Pacific region is growing rapidly due to increasing awareness and healthcare access.

How Are Technological Advances Shaping the Future of Gout Treatment?

Technological advancements in gout therapeutics are transforming the way the disease is managed, particularly with the rise of biologics and personalized medicine. Biologics like pegloticase, which is used to treat severe, refractory gout, have proven effective where traditional treatments have failed. Additionally, research into genetic markers and personalized treatment plans is gaining traction, allowing for tailored therapies based on an individual’s specific uric acid metabolism. Continuous innovation in drug delivery systems, such as extended-release formulations and injectable biologics, is enhancing patient compliance and providing more sustained control of uric acid levels. Moreover, telemedicine and digital health platforms are facilitating better patient-doctor communication, enabling real-time monitoring and adjustments to treatment plans, particularly for long-term management.

What Factors Are Driving the Growth in the Gout Therapeutics Market?

The growth in the gout therapeutics market is driven by several factors, including the increasing prevalence of gout worldwide, especially in developed nations where lifestyle-related risk factors such as poor diet and obesity are on the rise. The growing aging population, who are more susceptible to chronic conditions, is also boosting the demand for effective gout management. Furthermore, advancements in drug development, particularly the rise of biologics and novel urate-lowering therapies, are expanding treatment options for patients with refractory gout. Increased awareness of gout as a serious chronic condition, rather than just an acute issue, is driving earlier diagnosis and treatment, while improved healthcare infrastructure in emerging markets is broadening access to advanced therapies.

SCOPE OF STUDY

The report analyzes the Gout Therapeutics market by the following Segments, and Geographic Regions/Countries:

Segments:

Type (NSAIDs, Urate-Lowering Agents, Colchicine, Corticosteroids); Disease Condition (Chronic Gout, Acute Gout).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..

SELECT PLAYERS

AstraZeneca plc; GlaxoSmithKline plc; Grunenthal Group; Horizon Pharma Plc; Ironwood Pharmaceuticals, Inc.; JW Pharmaceutical; Merck& Co., Inc.; Novartis AG; Regeneron Pharmaceuticals.; Savient Pharmaceuticals; Selecta Biosciences, Inc.; Takeda Pharmaceutical Company Ltd.; Teijin Pharma Ltd.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Global Economic Update

Gout Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Prevalence of Gout and Associated Comorbidities Spurs Growth in Gout Therapeutics

Increasing Focus on Novel Drug Development Strengthens Business Case for Gout Therapeutics

Technological Advancements in Precision Medicine Drive Adoption of Personalized Gout Treatment

Growing Demand for Biologics Expands Addressable Market for Gout Therapeutics

Rising Geriatric Population Drives Demand for Effective Gout Management Solutions

Increasing Awareness of Chronic Gout and Treatment Options Spurring Market Demand

Rising Healthcare Expenditure and Access to Advanced Therapies Strengthen Growth in Developed Markets

Emergence of Novel Urate-Lowering Therapies Spurs Demand for Advanced Treatment Options

Growing Focus on Reducing Flare-Ups and Long-Term Management of Gout Drives Market Growth

Increasing Use of Combination Therapies for Better Management of Refractory Gout Expands Market

Patient Preference for Less Invasive and Effective Treatment Modalities Generates Demand

4. GLOBAL MARKET PERSPECTIVE

World Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Gout Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Urate-Lowering Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Urate-Lowering Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Urate-Lowering Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Colchicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Colchicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Colchicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Chronic Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Chronic Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Chronic Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Acute Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Acute Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Acute Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Gout Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

UNITED STATES

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

JAPAN

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

CHINA

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

EUROPE

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for Gout Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

FRANCE

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

GERMANY

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

UNITED KINGDOM

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

SPAIN

Spain Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

RUSSIA

Russia Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Gout Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

AUSTRALIA

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)

Australia Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

INDIA

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)

India Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

SOUTH KOREA

South Korea Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

REST OF ASIA-PACIFIC

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

LATIN AMERICA

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)

Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Latin America Historic Review for Gout Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

ARGENTINA

Argentina Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

BRAZIL

Brazil Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

MEXICO

Mexico Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

REST OF LATIN AMERICA

Rest of Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

MIDDLE EAST

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)

Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Middle East Historic Review for Gout Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

IRAN

Iran Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

ISRAEL

Israel Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

SAUDI ARABIA

Saudi Arabia Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

UNITED ARAB EMIRATES

UAE Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

REST OF MIDDLE EAST

Rest of Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

AFRICA

Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

Africa Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Arrowhead Pharmaceuticals, Inc.	%
Arthrosi Therapeutics	%
Boehringer Ingelheim International GmbH	%
Eisai Co., Ltd.	%
Hikma Pharmaceuticals Plc	%
Lannett Co., Inc.	%
Mochida Pharmaceutical Co., Ltd.	%
Synlogic	%
Takeda Pharmaceutical Co., Ltd.	%
Teijin Ltd.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll